Edwards Lifesciences Corp (EW)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total current assets	US$ in thousands	6,285,400	6,727,700	4,516,000	4,170,500	4,035,700	4,067,500	3,647,000	3,257,200	3,095,800	3,513,900	3,263,100	3,241,300	3,180,700	3,515,500	3,322,900	3,069,200	3,091,000	2,980,400	2,690,300	2,507,900
Total current liabilities	US$ in thousands	1,505,200	1,944,100	1,217,000	1,110,800	1,195,400	1,238,900	1,157,200	1,082,000	1,022,400	917,900	969,100	949,900	1,032,300	966,500	886,200	799,000	893,900	846,300	873,200	746,900
Current ratio		4.18	3.46	3.71	3.75	3.38	3.28	3.15	3.01	3.03	3.83	3.37	3.41	3.08	3.64	3.75	3.84	3.46	3.52	3.08	3.36

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $6,285,400K ÷ $1,505,200K
= 4.18

The current ratio of Edwards Lifesciences Corp has been relatively stable and consistently above 3 over the analyzed period from March 31, 2020, to December 31, 2024. This indicates that the company has consistently maintained a strong ability to meet its short-term obligations with its current assets. The current ratio peaked at 4.18 on December 31, 2024, suggesting a strong liquidity position at that point in time. However, there was a slight dip in the current ratio in the later part of 2022 and early 2023, potentially indicating temporary challenges in managing short-term liabilities with available current assets. Overall, the company's current ratio trend indicates a generally healthy liquidity position, providing a cushion to cover its short-term financial obligations effectively.